BMS to test Opdivo combined with Nektar’s NKTR214; terminated and superseded by new deal
Executive Summary
Bristol-Myers Squibb Co. agreed to evaluate a combination of its Opdivo (nivolumab) with Nektar Therapeutics’ NKTR214 in Phase I/II trials in five tumor types and seven indications. Nektar retains worldwide commercialization rights to NKTR214.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Immuno-Oncology
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
- Trial Collaborations
- R&D (No Licensing)
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice